Business Context and Reporting Period
Company: Amarin Corporation plc (Amarin)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2002
Business Overview: Amarin is a specialty pharmaceutical company focused on neurology and pain management. Its operations are split between a US-based marketing and distribution subsidiary (Amarin Pharmaceuticals, Inc.) and a Swedish-based drug delivery technology subsidiary (Amarin AB). The company's primary revenue driver is the Parkinson's disease drug Permax, alongside a "primary care portfolio" (Phrenilin, Bontril, Motofen) and licensing/royalty income.
Key Financial Metrics (Fiscal Year 2002)
| Metric | UK GAAP | US GAAP |
|---|---|---|
| Total Turnover | £40.6 million | £40.6 million |
| Net Loss | (£23.0 million) | (£20.8 million) |
| Loss Per Share (Basic) | (£2.48) | (£2.24) |
| Operating Loss (Continuing Ops) | (£20.3 million) | (£17.7 million) |
| Cash and Cash Equivalents | £15.1 million | £15.1 million |
| Total Shareholders' Equity | (£3.9 million) | (£5.4 million) |
| Long-Term Debt & Provisions | £22.8 million | £24.5 million |
Note: Financial statements are prepared under UK GAAP with reconciliations to US GAAP provided. The company reported a negative shareholders' equity position under both standards.
Material Changes vs. Prior Period
- Revenue Growth: Total turnover increased by 10% to £40.6 million from £36.9 million in 2001. This was driven primarily by Permax, which generated £26.4 million in revenue (compared to £18.6 million in 2001) due to a full year of sales following the acquisition of full US rights in March 2002.
- Significant Impairment Charges: The company recorded a non-recurring impairment charge of £23.8 million against the carrying value of Permax intangible assets. This was triggered by the launch of a generic version of Permax by Teva Pharmaceuticals in December 2002 and a Mayo Clinic article linking pergolide to valvular heart disease.
- Inventory Write-offs: A one-time charge of £2.9 million was recorded for inventory write-offs related to "Phrenilin with Caffeine and Codeine" due to intense generic competition, leading to the discontinuation of the product.
- Operating Expenses: Total operating expenses rose 64% to £42.2 million, largely due to the impairment charges and increased selling, general, and administrative (SG&A) costs associated with the expanded US sales force.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Liquidity: Management estimates it can fund operations through April 30, 2004, based on current cash balances and anticipated cash flows. However, the company explicitly states it will need to raise additional capital to fund new product acquisitions, development programs, and to repay significant debt obligations due in 2004 and 2005.
- Permax Decline: Prescriptions for Permax fell approximately 40% in the first two months of 2003 compared to the same period in 2002 due to generic competition and safety concerns. This decline is expected to materially adversely affect cash flows and earnings in 2003.
- Capital Raising: In January 2003, the company completed a private placement raising approximately £13.2 million. Proceeds were used to repay certain obligations to Elan Corporation plc (a major shareholder and related party).
Key Risks and Contingencies
- Generic Competition: The launch of generic Permax has significantly eroded market share. A second generic application is pending but stayed until September 2003 due to patent litigation.
- Product Liability: The company has received two notices of claims alleging personal injury/death from valvular heart disease associated with Permax. Litigation outcomes are uncertain.
- Supply Chain: Amarin relies on Eli Lilly for Permax supply. Lilly notified Amarin in March 2003 of its intent to terminate the supply agreement effective March 2006. Amarin must secure an alternate supplier within this timeframe.
- Related Party Dependence: The company has significant debt and deferred payment obligations to Elan Corporation plc. Failure to meet these obligations could result in the forfeiture of Permax rights.
- Development Risks: The company's pipeline includes LAX-101 (Huntington's disease) and Zelapar (Parkinson's). LAX-101 requires a further Phase III study, and Zelapar is awaiting FDA approval. Both depend on third-party partners (Laxdale and Elan) for development funding and regulatory success.
Investor Verification Checklist
- Debt Restructuring: Verify the terms of the January 2003 restructuring of debt owed to Elan Corporation plc and the impact on future cash flow obligations.
- Permax Sales Trajectory: Monitor quarterly prescription data for Permax to assess the severity of the decline caused by generic competition and safety warnings.
- Supply Agreement Transition: Confirm progress in identifying and qualifying a new manufacturer for Permax to replace Eli Lilly before the 2006 termination date.
- Capital Adequacy: Assess the company's ability to raise further equity or debt financing to meet 2004/2005 debt maturities and fund pipeline development.
- Legal Proceedings: Track the status of the patent litigation against Ivax Corporation (regarding generic Permax) and the product liability claims regarding valvular heart disease.
- Asset Disposal: Monitor efforts to sell the "primary care portfolio" or Amarin AB to generate cash for debt repayment, as agreed with Elan.